# Current Status of BTKi Treatment for CLL/SLL in China

> **NCT06508684** · — · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 1000 (estimated)

## Conditions studied

- CLL/SLL

## Interventions

- **DRUG:** BTK inhibitor

## Key facts

- **NCT ID:** NCT06508684
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-13
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-07-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508684, "Current Status of BTKi Treatment for CLL/SLL in China". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06508684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*